Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$24.88 USD
-1.09 (-4.20%)
Updated May 23, 2024 04:00 PM ET
After-Market: $24.87 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 21 - 40 ( 277 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for NTLA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looks to Shake Things Up with Ph 3 MAGNITUDE
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTLA-2001 Gets the Go Ahead for a Ph 3 in ATTR-CM
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Killikrein Stays Down Along with HAE Attacks
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Day 3 of ASGCT 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D